Quick Answer
Atrial fibrillation is the commonest sustained arrhythmia in adults and delivers 2 to 3 NEET PG questions per paper across Cardiology, Internal Medicine, and Pharmacology. The high-yield framework:
- Classify — paroxysmal (self-terminates within 7 days), persistent (over 7 days, needs cardioversion), long-standing persistent (over 1 year), permanent (accepted, no further rhythm attempts).
- Stroke risk — CHA2DS2-VASc score; anticoagulate if 2 or more in men (3 or more in women).
- Bleeding risk — HAS-BLED score; a high score is not a reason to withhold anticoagulation but to correct modifiable bleeding risks.
- Drug choice — DOAC first-line in non-valvular AF; warfarin mandatory in mechanical valves or moderate-severe rheumatic mitral stenosis.
- Rate vs rhythm — rate control (beta-blocker, non-DHP CCB, digoxin) for asymptomatic and older; rhythm control (amiodarone, flecainide, ablation) for young, symptomatic, or reversible AF.
- Cardioversion rule — direct if under 48 hours; otherwise anticoagulate 3 weeks before and 4 weeks after, or TEE-guided.
Atrial fibrillation (AF) sits at the intersection of stroke prevention, heart failure, and geriatric medicine — the exact zone NEET PG examiners love to test. The Indian context adds one more layer: rheumatic heart disease is still a leading AF aetiology, which flips the standard "DOAC first" answer on its head for a substantial minority of Indian patients.
This NEETPGAI deep dive covers classification, mechanism, ECG recognition, the CHA2DS2-VASc and HAS-BLED scores, DOAC versus warfarin selection, rate versus rhythm strategy, cardioversion rules, and the traps that turn up as vignette or drag-and-drop questions. Pair it with the Medicine subject hub and the heart failure guide for full cardiology fluency.
Classification of atrial fibrillation
Modern AF classification uses duration and clinical trajectory rather than aetiology.
| Type | Duration | Key feature |
|---|
| Paroxysmal | Under 7 days | Self-terminates spontaneously; often triggered by pulmonary vein ectopy |
| Persistent | Over 7 days | Does not self-terminate; needs pharmacological or electrical cardioversion |
| Long-standing persistent | Over 1 year | Continuous AF with a rhythm-control strategy still attempted |
| Permanent | Any | Physician and patient accept AF; no further attempts at rhythm control |
The older "valvular vs non-valvular" split has been sharpened — only mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis are now considered "valvular AF" that mandates warfarin. Every other valve lesion (including mitral regurgitation, aortic disease, and bioprosthetic valves after 3 months) counts as non-valvular AF for anticoagulation purposes.
Mechanism and triggers
Three mechanisms coexist in most patients:
- Focal ectopy from the pulmonary veins (dominant in paroxysmal AF; the substrate targeted by pulmonary vein isolation).
- Multiple wavelet re-entry in a diseased, dilated left atrium.
- Rotors — spiral waves of activation that anchor to fibrosed atrial tissue.
Common triggers and structural risk factors examiners test:
- Hypertension (commonest global cause).
- Valvular disease — especially rheumatic mitral stenosis in India.
- Ischaemic heart disease and prior MI.
- Hyperthyroidism (always check TSH in new-onset AF).
- Alcohol — the "holiday heart syndrome" after a binge.
- Pulmonary embolism and severe sepsis.
- Electrolyte disturbances (hypokalaemia, hypomagnesaemia).
- Obstructive sleep apnea.
- Post-cardiac surgery (peaks day 2 to 3).
- Genetic predisposition (KCNQ1, PITX2 loci).
Clinical features and ECG
Symptoms range from asymptomatic (30 percent, often detected incidentally) to palpitations, dyspnea, fatigue, chest discomfort, presyncope, and frank syncope. Silent AF is not benign — the stroke risk is identical to symptomatic AF.
ECG hallmarks
- Irregularly irregular narrow-complex tachycardia.
- Absent P waves replaced by fibrillatory (f) waves at 350 to 600 per minute.
- Ventricular rate typically 100 to 160 bpm in untreated AF; slower rates suggest AV nodal disease or drug effect.
- Ashman phenomenon — aberrantly conducted beat after a short RR cycle preceded by a long RR cycle (can mimic PVC).
- Wide-complex AF with rates above 200 bpm should raise Wolff-Parkinson-White with pre-excited AF — avoid AV nodal blockers, use procainamide or DC cardioversion.
Complications
- Thromboembolic stroke — five-fold increase in risk; usually cardioembolic with large-vessel occlusion.
- Tachycardia-induced cardiomyopathy — chronic rapid ventricular rates cause reversible LV dysfunction; HR control alone restores EF.
- Heart failure decompensation — loss of atrial kick reduces cardiac output by up to 25 percent.
- Haemodynamic instability — angina, hypotension, and shock in patients with limited reserve.
Stroke risk stratification — CHA2DS2-VASc
The CHA2DS2-VASc score is the guideline-recommended tool for non-valvular AF.
| Criterion | Points |
|---|
| Congestive heart failure | 1 |
| Hypertension | 1 |
| Age 75 or above | 2 |
| Diabetes mellitus | 1 |
| Prior Stroke, TIA, or thromboembolism | 2 |
| Vascular disease (prior MI, PAD, aortic plaque) | 1 |
| Age 65 to 74 | 1 |
| Sex category female | 1 |
Anticoagulation thresholds:
- Men score 0 or women score 1 → no anticoagulation.
- Men score 1 or women score 2 → consider anticoagulation.
- Men score 2 or above, women score 3 or above → oral anticoagulation indicated.
Bleeding risk — HAS-BLED
HAS-BLED (Hypertension, Abnormal renal or liver function, Stroke history, Bleeding, Labile INR, Elderly over 65, Drugs or alcohol) predicts major bleeding. A score of 3 or more is high risk, but this is not a reason to withhold anticoagulation — it is a prompt to correct modifiable risk factors (BP control, alcohol reduction, review of concurrent antiplatelets and NSAIDs) and to schedule closer follow-up.
Anticoagulation — DOAC versus warfarin
DOACs (first-line in non-valvular AF)
- Apixaban 5 mg BD (2.5 mg BD if any two of age 80+, weight 60 kg or less, creatinine 1.5 or above).
- Rivaroxaban 20 mg once daily with food (15 mg if CrCl 15 to 50).
- Dabigatran 150 mg BD (110 mg BD if age 80+ or bleeding risk high).
- Edoxaban 60 mg once daily (30 mg if CrCl 15 to 50 or weight 60 kg or less).
Advantages — no INR monitoring, fewer food and drug interactions, lower intracranial haemorrhage, rapid onset and offset, specific reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors).
Warfarin (mandatory in valvular AF)
Warfarin is the only oral anticoagulant proven safe in mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis. Target INR 2 to 3 (2.5 to 3.5 for mechanical mitral valves). Time in therapeutic range (TTR) above 65 percent predicts good outcomes.
The Indian reality — rheumatic AF remains common, and many district hospitals still rely on warfarin because DOACs are unaffordable or INR facilities are scarce in rural belts. The RE-ALIGN trial confirmed that dabigatran is inferior to warfarin in mechanical valves, a favourite MCQ distractor.
Left atrial appendage occlusion (LAAO)
The Watchman device (percutaneous LAAO) and surgical LAA clipping (during concomitant cardiac surgery) are alternatives for patients with contraindications to long-term anticoagulation — recurrent bleeding, high fall risk, or intolerance.
Rate versus rhythm control
The AFFIRM and RACE trials showed no mortality difference between rate and rhythm strategies for older patients with minimal symptoms, but the more recent EAST-AFNET 4 trial (2020) showed that early rhythm control within one year of diagnosis reduces cardiovascular events.
Rate control — preferred when
- Older, minimally symptomatic patients.
- Persistent or long-standing AF unlikely to remain in sinus rhythm.
- Comorbidities that make antiarrhythmics risky.
Agents:
- Beta-blockers (metoprolol, bisoprolol, carvedilol) — first-line, especially with heart failure or ischaemic heart disease.
- Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) — good for reactive airway disease; avoid in HFrEF.
- Digoxin — useful in sedentary patients and HFrEF; poor control during exertion; watch for toxicity in renal impairment.
- Combination therapy (beta-blocker plus digoxin) when monotherapy fails.
Target heart rate — RACE II established that a lenient target of resting HR less than 110 bpm is non-inferior to strict control (less than 80 at rest, less than 110 on moderate exertion) in asymptomatic patients. Strict control is reserved for persistent symptoms or tachycardia-induced cardiomyopathy.
Rhythm control — preferred when
- Young, symptomatic patients.
- First episode of AF.
- Reversible trigger (thyrotoxicosis, alcohol, sepsis).
- AF-mediated heart failure.
- Failure of rate control.
Antiarrhythmics:
- Amiodarone — most effective; used in structural heart disease; long-term thyroid, liver, lung, and skin toxicity limits chronic use.
- Flecainide and propafenone — Class Ic; effective in structurally normal hearts; contraindicated in ischaemic heart disease and structural disease (CAST trial).
- Dofetilide and sotalol — Class III; require QT monitoring and hospital initiation.
- Dronedarone — safer than amiodarone but contraindicated in NYHA III to IV heart failure and permanent AF (PALLAS trial).
Catheter ablation — pulmonary vein isolation is the definitive rhythm-control option, with 60 to 80 percent single-procedure success in paroxysmal AF and 50 to 60 percent in persistent AF. CASTLE-AF showed ablation reduces mortality and heart failure hospitalisation in AF with heart failure.
Cardioversion — when and how
Emergency DC cardioversion
Synchronised DC shock 200 J biphasic is indicated for haemodynamic instability (hypotension, active ischaemia, pulmonary edema) regardless of AF duration.
Elective cardioversion — the 48-hour rule
- AF less than 48 hours and stable — cardiovert without preceding anticoagulation.
- AF longer than 48 hours or unknown duration — either three weeks of therapeutic anticoagulation before, or transesophageal echo (TEE) to exclude LA appendage thrombus.
- After cardioversion — four weeks of anticoagulation is mandatory in every case, because atrial stunning maintains a thromboembolic risk even after sinus rhythm returns.
Pharmacological cardioversion uses IV flecainide, propafenone, ibutilide, or amiodarone depending on structural heart disease and QT status.
NEET PG MCQ traps
- Rheumatic AF drug choice — moderate-to-severe MS with AF needs warfarin, not a DOAC. RE-ALIGN and Indian rheumatic-AF vignettes are common.
- 48-hour cardioversion cutoff — three weeks of anticoagulation before elective cardioversion is required for AF over 48 hours; "start warfarin and cardiovert the same day" is the wrong-answer distractor.
- Post-cardioversion anticoagulation — four weeks is mandatory even in low-risk patients.
- WPW with pre-excited AF — wide, irregular, fast tachycardia. AV nodal blockers (adenosine, verapamil, digoxin, beta-blockers) can precipitate VF. Use procainamide or DC cardioversion.
- Ashman phenomenon — long-short cycle before a wide beat is aberrancy, not ectopy.
- Lenient rate control — RACE II says under 110 is non-inferior to under 80.
- Holiday heart — new AF after alcohol binge in a young patient; usually reverts, no chronic anticoagulation if CHA2DS2-VASc is 0 or 1.
- Dabigatran and mechanical valves — contraindicated (RE-ALIGN).
- Flecainide in structural heart disease — contraindicated (CAST).
- Silent AF stroke risk — identical to symptomatic AF; do not withhold anticoagulation because symptoms resolved.
Indian context
- Rheumatic AF — mitral stenosis remains a leading AF aetiology in India, especially in young women. Warfarin, INR monitoring, and secondary prophylaxis with benzathine penicillin are mandatory.
- DOAC access — apixaban and rivaroxaban generics are now available in India at 10 to 20 percent of the branded cost, improving access; dabigatran and edoxaban remain relatively expensive.
- INR monitoring — rural INR laboratories are patchy; point-of-care INR devices and community-based anticoagulation clinics are expanding.
- Opportunistic AF screening — single-lead ECG smartphone devices (KardiaMobile, Apple Watch) are increasingly used to detect silent AF in over-65s and hypertensives.
- Post-stroke workup — every young stroke in India warrants Holter or extended ambulatory rhythm monitoring to rule out paroxysmal AF, especially when rheumatic heart disease is suspected.
Frequently asked questions
When should a DOAC be chosen over warfarin in atrial fibrillation?
DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin for stroke prevention in non-valvular AF because they have equal or superior efficacy, lower intracranial bleeding, no INR monitoring, and fewer drug and food interactions. Warfarin remains mandatory in mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis, which is still common in India.
How is the CHA2DS2-VASc score calculated?
CHA2DS2-VASc awards one point each for congestive heart failure, hypertension, diabetes, vascular disease, age 65 to 74, and female sex, and two points each for age 75 or above and prior stroke or TIA. A score of 2 or more in men (3 or more in women) mandates oral anticoagulation; a score of 0 in men or 1 in women needs no anticoagulation.
When is cardioversion safe without prior anticoagulation?
Direct cardioversion is safe if AF duration is clearly less than 48 hours and the patient is haemodynamically stable. For AF longer than 48 hours or of unknown duration, either give three weeks of therapeutic anticoagulation before cardioversion or perform a transesophageal echo to exclude left atrial thrombus. Four weeks of anticoagulation after cardioversion is mandatory in every case.
What is the rate-control target in atrial fibrillation?
The RACE II trial showed that a lenient target of resting heart rate less than 110 bpm is non-inferior to a strict target of less than 80 bpm at rest and less than 110 with moderate exercise. Lenient control is now preferred in asymptomatic patients. Strict control is reserved for persistent symptoms or tachycardia-induced cardiomyopathy.
Which patients with AF benefit most from rhythm control?
Young patients, first episode of AF, symptomatic despite rate control, AF with a reversible trigger (thyrotoxicosis, alcohol, sepsis), and AF-related heart failure benefit from rhythm control. The EAST-AFNET 4 trial also showed that early rhythm control within one year of diagnosis reduces cardiovascular events. Catheter ablation with pulmonary vein isolation is 60 to 80 percent effective after a single procedure in paroxysmal AF.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: September 2026
